Alterations in the intestinal microbiota of patients with severe and active Graves' orbitopathy: a cross-sectional study/Experiment 1

From BugSigDB


Reviewed Marked as Reviewed by Fatima on 2021/07/16

Curated date: 2021/01/10

Curator: WikiWorks

Revision editor(s): Fatima, Rimsha, WikiWorks

Subjects

Location of subjects
China
Host species Species from which microbiome was sampled. Contact us to have more species added.
Homo sapiens
Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
Graves ophthalmopathy Congestive Ophthalmopathy,Dysthyroid Ophthalmopathy,dysthyroid/thyroid-associated orbitopathy (TAO),Edematous Ophthalmopathy,Graves' ophthalmopathy,Graves' orbitopathy,Myopathic Ophthalmopathy,thyroid eye disease (TED),Thyroid-Associated Ophthalmopathies,Thyroid-Associated Ophthalmopathy,Graves ophthalmopathy,graves ophthalmopathy
Group 0 name Corresponds to the control (unexposed) group for case-control studies
Healthy controls
Group 1 name Corresponds to the case (exposed) group for case-control studies
graves orbitopathy
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
The diagnosis of GO was established according to the EUGOGO Guidelines. The active GO was defined by a clinical activity score (CAS)≥3/7, and the severe GO was defined by NOSPECS score≥IV. CT or MRI was used to exclude any orbital space-occupying disease such as tumor or extraocular myositis.
Group 0 sample size Number of subjects in the control (unexposed) group
32
Group 1 sample size Number of subjects in the case (exposed) group
33
Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
4 weeks

Lab analysis

Sequencing type
16S
16S variable region One or more hypervariable region(s) of the bacterial 16S gene
V4
Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
Ion Torrent

Statistical Analysis

Statistical test
Metastats
Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
0.05
MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
No
Matched on Factors on which subjects have been matched on in a case-control study
age, sex

Alpha Diversity

Shannon Estimator of species richness and species evenness: more weight on species richness
decreased
Chao1 Abundance-based estimator of species richness
unchanged
Simpson Estimator of species richness and species evenness: more weight on species evenness
decreased
Richness Number of species
unchanged

Signature 1

Reviewed Marked as Reviewed by Fatima on 2021/07/16

Curated date: 2021/01/10

Curator: Rimsha Azhar

Revision editor(s): LGeistlinger, Fatima, Rimsha, WikiWorks

Source: Figure 4a, 4b, 4c

Description: Comparison of the bacterial abundance at the phylum, genus and species levels in patients with graves' orbitopathy and healthy controls

Abundance in Group 1: increased abundance in graves orbitopathy

NCBI Quality ControlLinks
Bacteroidota
Segatella copri
unclassified Prevotellaceae

Revision editor(s): LGeistlinger, Fatima, Rimsha, WikiWorks

Signature 2

Reviewed Marked as Reviewed by Fatima on 2021/07/9

Curated date: 2021/01/10

Curator: Rimsha Azhar

Revision editor(s): Fatima, Rimsha, WikiWorks

Source: Figure 4a, 4b, 4c

Description: Comparison of the bacterial abundance at the phylum, genus and species levels in patients with graves' orbitopathy and healthy controls

Abundance in Group 1: decreased abundance in graves orbitopathy

NCBI Quality ControlLinks
Alistipes shahii
Anaerobutyricum hallii
Anaerostipes
Blautia
Butyricimonas
Collinsella
Eubacterium ventriosum
Bacillota
Fusicatenibacter
Marseillibacter massiliensis
Phocaeicola massiliensis
Ruminococcus

Revision editor(s): Fatima, Rimsha, WikiWorks